Elevate OA Support: The Synergy of Univestin™ & AmLexin™

New published clinical research on Univestin™ and AmLexin™ in combination has shown positive synergistic effects, for Osteoarthritis (OA) and overall joint health¹. Studies show that these ingredients work effectively together to help reduce pain sensitivity while supporting the preservation of the articular cartilage matrix integrity composition.

The research highlights how the pairing of these two well-known US brands may provide a powerful, synergistic approach to joint support for healthy aging.

Moreover, both ingredients have scientific evidence proving their individual benefits. Univestin™ for its fast-acting effects by alleviating joint discomfort and stiffness within 3-7 days, and AmLexin™ for its effectiveness in articular cartilage support.

Research on Univestin™ has shown that doses of 250mg/day and 500mg/day were significantly more effective than the alternative drug (Celecoxib at 200mg/day) for reducing joint stiffness and joint function incapacity caused by OA². Complementing this, AmLexin™ has clinical research showing that a dose of 400mg/day over 12 weeks, can significantly reduce uCTX-II (the most well-validated biomarker in osteoarthritis) by 8.9%, compared to alternative treatments³.

The results of this new research, and various individual studies on both ingredients, demonstrates how Univestin™ and  AmLexin™ could potentially be an alternative, plant-based, natural solution for the management of OA and/or its associated symptoms, by enhancing the anti-inflammatory and analgesic action of Univestin™ with the cartilage degradation support from AmLexin™. 

To learn more about these innovative ingredients, visit our Health Platform or speak to a member of the team!

_{References
(1) Yimam M et al. (2017) Cartilage Protection and Analgesic Activity of a Botanical Composition Comprised of Morus alba, Cartilage Protection and Analgesic Activity of a Botanical Composition Comprised of Morus alba, Scutellaria baicalensis, and Acacia catechu baicalensis, and Acacia catechu,Evid Based Complement Alternat Med. 2017 Aug 20;2017:7059068. doi: 10.1155/2017/7059068
(2) Sampalis J., L.A. Brownell. 2012. A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin. Nutrition Journal. 11(21). doi:10.1186/1475-2891-11-21.
(3) Kalman DS, Hewlings SJ. The Effects of Morus albaand Acacia catechuon Quality of Life and Overall Function in Adults with Osteoarthritis of the Knee. J Nutr Metab. 2017;2017:4893104. doi: 10.1155/2017/4893104. Epub 2017 Sep 11. PMID: 29085676; PMCID: PMC5612321.}